News Releases

CUPERTINO, Calif., Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences. 

• James E. Brown, President and CEO, will present at the Rodman & Renshaw Global Investment Conference on Tuesday, September 12 at 12:30 p.m. Eastern time. The conference is being held at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/rrshq27/drrx.Management will also be available for one-on-one meetings at this conference on Tuesday, September 12; interested institutional investors should request a one-on-one meeting through the conference coordinators.
• James E. Brown, President and CEO, will also present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25 at 3:00 pm Eastern Time. The conference is being held at the InterContinental New York Barclay Hotel. A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/cantor6/drrx. Management will also be available for one-on-one meetings at this conference on Monday, September 25; interested institutional investors should request a one-on-one meeting through the conference coordinators.

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms.  DUR-928, a new chemical entity in Phase 1 development, is the lead candidate in DURECT's Epigenetic Regulator Program.  An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival.  Human applications may include acute organ injury, chronic metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and other liver diseases with both broad and orphan populations, and inflammatory skin conditions such as psoriasis.  DURECT's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR^® (SABER^®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery.  Another late stage product candidate is REMOXY^® ER (oxycodone), an investigational pain control drug based on DURECT's ORADUR^® technology.  For more information, please visit www.durect.com.

NOTE: POSIMIR^®, SABER^®, and ORADUR^® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  POSIMIR, DUR-928, REMOXY ER and ORADUR-Methylphenidate ER are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation